drugset / Trial / NCT00004039
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy plus interferon alfa or rituximab in treating patients who have high risk stage III or stage IV lymphoma.
Timeline
- Start
- 1998-06
- Primary completion
- 2000-01
- Completion
- 2000-01
Outcome
Outcome not reported
Stopped (Enrollment): “No patient accruals”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Vincristine | Small molecule | — | Intravenous |
| Subject | interferon alfa | Protein / enzyme biologic | — | Subcutaneous |